Key insights
- 4D Path secured funding to develop cancer therapy biomarkers, appointing new board members with experience from Celgene and Baxalta. Baxter International reported strong Q1 earnings, exceeding expectations and boosting pre-market stock performance. This signals positive momentum in the healthcare sector, potentially influencing investor sentiment towards related equities.
NEWTON, Mass. - 4D Path announced the first close of a strategic financing round to develop treatment predictive biomarkers for cancer therapy, according to a press release statement.
The company appointed Katherine Vega Stultz and Robert J. Hombach to its Board of Directors. Stultz will serve as Board Chair.
Stultz previously directed the clinical project organization at Celgene, overseeing over 30 mid and late stage clinical programs across hematology and oncology. She currently serves as CEO and President of BrainXell Therapeutics Global Inc.
Hombach served as Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta (NYSE:BXLT) until its acquisition by Shire plc. in 2016. He has served on audit, finance and compensation committees for several public and private boards, including BioMarin (NASDAQ:BMRN) and Seaport Therapeutics.
The company stated it has delivered results across breast, ovarian, colorectal and skin cancers in both early-stage and metastatic cases.
4D Path uses its Q-Plasia OncoReader platform to measure cell cycle deregulation and tumor immune microenvironment dynamics for predicting patient response to therapy. The financing will support development of biomarkers for clinical use and partnerships with biopharmaceutical companies.
Jacopo Leonardi, CEO of 4D Path, said the board additions and financing will help advance the treatment predictive technology.
In other recent news, Baxter International Inc. reported a stronger-than-expected performance for the first quarter of 2026. The company achieved earnings per share (EPS) of $0.36, surpassing analyst projections of $0.32, marking a 12.5% earnings surprise. Baxter also reported revenue of $2.7 billion, exceeding expectations by 3.05%. These results indicate a positive start to the year despite the challenges the company faces. In addition to its earnings news, Baxter’s stock experienced a rise in pre-market trading, reflecting investor optimism. These developments are significant for investors monitoring the company’s financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.